Daniel Hochstrasser nominated as a new member of Novartis Board of Directors

Bär & Karrer partner Daniel Hochstrasser (pictured) has been nominated for election to the Board of Directors of Novartis, a global healthcare company based in Switzerland, which will take place at the Annual General Meeting on March 4, 2022.  

Daniel Hochstrasser will leave the Bär & Karrer partnership at the end of 2022 after 29 years in the law firm, 10 of which as a senior partner. 

Daniel Hochstrasser is currently serving as co-head of arbitration at Bär & Karrer. In his practice, he focuses on conducting arbitration and litigation, in particular in connection with disputes arising from m&a transactions, industrial and infrastructure projects, banking and finance as well as license, distribution and development agreements, especially in the pharmaceutical sector. 

Daniel Hochstrasser nominated as a new member of Novartis Board of Directors



Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website www.lcpublishinggroup.com

LC srl – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 10.000,00 i.v.

Copyright 2022 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram